Albany Molecular Research, Inc. Renews Relationship with Eli Lilly and Company
Albany Molecular Research, Inc. announced a new drug discovery research agreement with Eli Lilly and Company, continuing an ongoing relationship between the two companies that began in 1998. Under the terms of the agreement, AMRI will provide fee-for-service chemistry research on projects in strategic therapeutic areas identified by Lilly. Though specific financial details were not disclosed, the contract includes fee-for-service provisions and is a continuation of a recently expired agreement.
"We believe that Lilly's decision to continue this significant relationship with AMRI reflects the value that AMRI's scientists have been able to bring to the collaboration," said AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D.
Other news from the department business & finance
